RegulatoryMay 21, 2026, 05:12 PM
Quince Therapeutics Regains Nasdaq Listing Compliance
AI Summary
Quince Therapeutics, Inc. announced that it has regained compliance with Nasdaq's continued listing requirements. The company had previously received a notice on March 17, 2026, for failing to maintain a minimum market value of listed securities of $50,000,000. On May 20, 2026, Nasdaq confirmed that Quince Therapeutics now complies with the stockholders' equity rule, based on its reported $15,672,000 in stockholders' equity for the quarter ended March 31, 2026, thereby closing the matter.
Key Highlights
- Quince Therapeutics received a Nasdaq notice on March 17, 2026, for failing to maintain a $50,000,000 minimum market value of listed securities (MVLS).
- On May 20, 2026, Nasdaq confirmed the company's compliance with Listing Rule 5450(b)(1)(A).
- Compliance was regained based on stockholders' equity of $15,672,000 reported in the Q1 2026 Form 10-Q.
- The matter regarding Nasdaq continued listing requirements is now closed.
Price Impact
More from QNCX